The discovery of a weekly vaccine for weight loss is a game-changer in obesity medicine

The discovery of a weekly vaccine for weight loss is a game-changer in obesity medicine

A new weight-loss injection is being hailed as a ‘game changer’ – with the potential to cut diabetes risk by 50% and ‘fight obesity as a disease’ for the first time, according to a new study .

The research, conducted by the University of Alabama, found that weekly injections of the drug semaglutide in overweight and obese research participants caused an average weight loss of 37 pounds.

“We haven’t seen this degree of weight loss with any prior drug,” the study’s lead author, Dr. Timothy Garvey, said in a statement. “Over 50% of trial participants lost 15% of their body weight, and between one-third and 40% of participants lost 20% of their body weight.”

Researchers have revealed new findings about a weight-loss drug that may reduce the risk of type 2 diabetes.
Getty Images/iStockphoto

The research findings “begin to close the gap with bariatric surgery” in terms of “sufficiency to treat or prevent a wide range of obesity complications that impair health and quality of life,” according to Garvey. , who called her a “game changer”. in obesity medicine” with the potential to “treat obesity as a disease”.

Man measuring stomach
The trials found a sharp drop in diabetes risk and weight, signaling that increasing the dosage of the drug could be a “game changer”.
Getty Images/iStockphoto

This is good news for Americans who are fighting a losing battle against fat: between 1960 and 2010, the prevalence of obesity among adults in the United States nearly tripled, from 13% to 36%, according to Centers for Disease Control and Prevention.

“Many in the lay public and many health care professionals also think of obesity primarily as a lifestyle choice, even today, despite our scientific understanding of obesity as a disease,” said said Garvey. “That’s why I think these trials are important.”

Trials of the effect of semaglutide treatment in obese people, known as STEPs, studied patients who received semaglutide compared to those who received a dose of placebo.

The researchers administered a dose of 2.4 milligrams to 1,961 patients in the first trial and 803 in the second. Additionally, scientists used a cardiometabolic disease staging formula to predict the likelihood of developing type 2 diabetes.

Wegovy, already approved in England, showed promising results in trials.

In the first trial, the 10-year risk score of people who received the drug fell by 61%, while participants who received the placebo pills only lowered their risk score by 13%.

While the formula focused on diabetes, the study authors found that the drug could also prevent and treat cardiovascular disease and its associated complications like osteoarthritis and sleep apnea.

“That means treating and preventing the consequences and complications of their obesity that are responsible for harming health: preventing progression to diabetes, sleep apnea, osteoarthritis and things like that,” Garvey said. “If approved, Semaglutide 2.4 milligrams has the potential to truly change the way we think about treating this disease of obesity.”

The groundbreaking findings have earned a place in the New England Journal of Medicine for the STEP 1 trial and in the Journal of the American Medical Association for the STEP 3 trial.

Semaglutide was first approved by the Food and Drug Administration at the lower 1-milligram dose known under the brand name Ozempic, but the 2.4-milligram dose has shown more promising results – and pharmaceutical manufacturer Novo Nordisk got FDA approval last year. At the time, the price was around $1,627 per month before insurance.

#discovery #weekly #vaccine #weight #loss #gamechanger #obesity #medicine

Leave a Comment

Your email address will not be published.